Pipeline

Fibrotic Diseases

Glympse is filling the diagnostic and prognostic void in Non-Alcoholic Steatohepatitis (NASH), a disease that impacts 16 million people in the U.S. and 100 million worldwide.

We are paving the way to improve the continuum of care for NASH and build a comprehensive understanding of the disease trajectory that doesn’t currently exist. Glympse’s biosensors safely, noninvasively, and accurately predict specific stages of NASH, and have shown potential to reliably measure response to therapy long before histopathology changes become visible.

Glympse’s technology avoids the difficulties seen with needle liver biopsy by providing a safe, repeatable, noninvasive measure of disease activity directly at the liver.

Oncology

Cancer impacts 14 million patients in the U.S. and 50 million worldwide.

Glympse is targeting specific biology to query and directly track the progression of certain cancers and the response to treatment longitudinally across a broad range of immunotherapies, targeted therapies, and other standards-of-care.

Glympse’s technology is measuring the response to a therapy in real-time and provides a functional readout that shows not only that a tumor is responding, but how biologically the tumor is responding to a given therapy.

Additional therapeutic areas

Our development pipeline features programs in infectious disease, as well as preclinical validation in additional diseases.